(NASDAQ: PGEN) Precigen's forecast annual revenue growth rate of 275.35% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.07%.
Precigen's revenue in 2026 is $6,309,000.On average, 5 Wall Street analysts forecast PGEN's revenue for 2026 to be $35,569,976,884, with the lowest PGEN revenue forecast at $26,526,222,690, and the highest PGEN revenue forecast at $45,388,606,732. On average, 4 Wall Street analysts forecast PGEN's revenue for 2027 to be $74,200,535,685, with the lowest PGEN revenue forecast at $65,188,625,696, and the highest PGEN revenue forecast at $82,918,771,341.
In 2028, PGEN is forecast to generate $119,497,148,047 in revenue, with the lowest revenue forecast at $114,812,511,681 and the highest revenue forecast at $123,014,163,567.